Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2003): Abe M+, Intern Med 42(1), 48
(2003): Bamberg C+, Hautarzt 54(9), 864
(2000): Goldstein NS+, Am J Clin Pathol 114(4), 591
(2000): Nietsch HH+, Am J Gastroenterol 95(10), 2993
(1998): Bhat G+, J Clin Gastroenterol 27(1), 74
(1998): Teitelbaum JE+, Arch Pediatr Adolesc Med 152(11), 1132
(1997): Herzog D+, Dig Dis Sci 42(5), 1100
(1996): Malcolm A+, Am J Gastroenterol 91(8), 1641
Hypersensitivity
(2005): Trivin C+, Therapie 60(6), 590
(2003): Roca B+, IntensiveCareMed29(2), 338
(2002): Murray C+, World Congress Dermatol Poster, 0120
(2002): Parc C+, Br J Ophthalmol 86(11), 1313
(2002): Rahman Z+, Int J Dermatol 41(8), 530
(2001): Bachelz H+, Arch Dermatol 137, 69
(2001): Colvin JH+, Pediatr Dermatol 18(4), 295
(2000): Gil P, Ann Dermatol Venereol 127(10), 841
(1999): Antunes A+, Ann Dermatol Venereol 126, 518
(1999): Clayton BD+, Arch Dermatol 135, 139
(1999): Lupton JR+, Cutis 64, 91 (infectious-mononucleosis-like)
(1999): Piette AM+, Rev Med Interne (French) 20, 869
(1998): Dutz J, Vancouver, Canada (from Internet) (observation)
(1998): Schlienger RG+, Epilepsia 39, S3 (passim)
(1997): Hoefnagel JJ+, Ned Tijdschr Geneeskd (Dutch) 141, 1424
(1997): MacNeil M+, JAmAcadDermatol36, 347
(1997): Shapiro LE+, Arch Dermatol 133, 1224
(1995): Parneix-Spake A+, Arch Dermatol 131, 490
(1994): Sitbon O+, Arch Intern Med 154, 1633
Myalgia/Myositis/Myopathy/Myotoxicity
(2004): Narvaez J+, Am J Med 116(4), 282
(2001): Gordon MM+, J Rheumatol 28(5), 1004
(1998): Matteson EL+, J Rheumatol 25, 1653
(1998): Pavese P+, Ann Med Interne (Paris) 149(8), 521
Nephrotoxicity
(2003): Sethi S+, Am J Kidney Dis 42(2), E27
Polyarteritis nodosa
(2007): Tehrani R+, J Clin Rheumatol 13(3), 146
(2006): Abad S+, Arthritis Rheum 55(5), 831
(2006): Katada Y+, Mod Rheumatol 16(4), 256
(2005): Culver B+, Arthritis Rheum 53(3), 468
(2003): Pelletier F+, Eur J Dermatol 13(4), 396
(2001): Schaffer JV+, JAmAcadDermatol44, 198
(1999): Schrodt BJ+, Pediatrics 103, 503
Pseudo-mongolian spot
(1992): Ridgway HB+, Arch Dermatol 128, 565
Rhabdomyolysis
(2002): Rahman Z+, Int J Dermatol 41(8), 530
Serum sickness (3–5%)
(2001): Arch Dermatol 137, 100 (2 cases)
(1999): Elkayam O+, Semin Arthritis Rheum 28, 392
(1998): Martinez JA+, Med Clin (Barc) (Spanish) 111, 198
(1997): Blumenthal HL, Beachwood, OH (personal case)
(observation)
(1997): Hoefnagel JJ+, Ned Tijdschr Geneeskd (Dutch) 141, 1424
(1997): Shapiro LE+, Arch Dermatol 133, 1224
(1997): Zabawski E, Dallas, TX (from Internet) (observation)
(1996): Harel L+, Ann Pharmacother 30, 481
(1996): Levenson T+, Allergy Asthma Proc 17, 79
(1990): Puyana J+, Allergy 45, 313
Upper respiratory infection
(2006): NINDS NET-PD, Neurology 66(5), 664 (26%)
MINOXIDIL
Trade names: Alopexy; Apo-Gain; Hairgaine; Loniten (Par);
Lonolox; Lonoten; Minoximen; Regaine; Rogaine (topical) (Pfizer)
Indications: Hypertension, androgenetic alopecia
Category: Vasodilator
Half-life: 4.2 hours
Clinically important, potentially hazardous interactions
with: alcohol, guanethidine
Note: For topical reaction patterns, I have added a bracket [T]
Reactions
MINOXIDIL 371
Skin
Acne
(1985): Baral J, JAmAcadDermatol13, 1051 (scalp comedones)
Allergic reactions (sic) [T]
Bullous dermatitis (10%) [T]
Erythema [T]
Erythema multiforme
(1981): DiSantis DJ+, Arch Intern Med 141, 1515
Erythroderma
(1988): Ackerman BH+, Drug Intell Clin Pharm 22, 703
Exanthems
(1988): Ackerman BH+, Drug Intell Clin Pharm 22, 703
(1981): Campese VM, Drugs 22, 257
(1981): DiSantis DJ+, Arch Intern Med 141, 1515
Folliculitis [T]
(1996): Duvic M+, JAmAcadDermatol35, 74
Lupus erythematosus
(1987): Tunkel AR+, Arch Intern Med 147, 599
(1981): Mitas JA, Arthritis Rheum 24, 570
Peripheral edema (7%)
Pigmentation
Pruritus [T]
(1996): Duvic M+, JAmAcadDermatol35, 74
(1990): Colamarino R+, AnnInternMed113, 256
Pyogenic granuloma
(1989): Baran R, Dermatologica 179(2), 76 (explosive, of the
scalp)
Rash (sic) (